Association between pharmacological tenofovir adherence measures and subsequent 24-week viral load outcomes for people living with HIV in South Africa
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Objective measures of antiretroviral therapy (ART) adherence, such as tenofovir (TFV) concentrations, may allow for targeted interventions to prevent future HIV viraemia. We evaluated three TFV adherence measures and their association with current and 24-week viral load (VL) outcomes.
Methods
In a sub-study of the South African-based POwER trial, we measured urine TFV using a point-of-care (POC) antibody-based assay and two metrics assessed via liquid-chromatography-mass-spectrometry: quantitative urine TFV, and TFV-diphosphate (TFV-DP) concentrations in dried blood spots (DBS). We assessed the association between current and subsequent 24-week VL outcomes and these three measures using logistic regression models. We also compared the baseline characteristics of individuals with detectable vs. undetectable POC urine TFV results at enrolment.
Results
Of 124 participants, 54.8% female, median age 39 years, 101 (81.5%) had detectable POC urine TFV and 23 (18.5%) did not. Higher TFV-DP concentrations in DBS were negatively associated with viraemia after 24-weeks (OR 0.83, 95% CI 0.725-0.928, p=0.003), whilst a detectable POC urine TFV (OR 0.62, 95% CI 0.22-1.82, p=0.380) and quantitative urine TFV (OR 0.98, 95% CI 0.95-1.00, p=0.153) showed no significant association. Compared to those with detectable POC urine TFV, those with undetectable POC urine TFV were more likely to be concurrently viraemic at enrolment (78.3% vs 25.7%, p<0.001) and have a CD4 count <200 cells/uL (34.8% vs 12.9%, p=0.001).
Conclusion
DBS TFV-DP was associated with viraemia at 24-weeks and could help predict future viraemia. Undetectable POC urine TFV was associated with recent ART initiation, current viraemia, and lower CD4 count.
Trial registration
Pan African Clinical Trials Registry (PACTR202001785886049) and the South African Clinical Trials Registry (DOH-27-072020-6890).
